Supplementary Table S2 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment

Supplementary Table S2 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment

<p>The relationship between NPM1 dependency and cell line metastatic propensity, determined from genome-wide CRISPR-Cas9 screens (https://depmap.org/portal/interactive). A score of zero indicates that a gene is not essential. Common essential genes have a median score of -1. A lower score indi...

保存先:

書誌詳細
第一著者:	Konjeti R. Sekhar (15400345) (author)
その他の著者:	Michael L. Freeman (15400348) (author)
出版事項:	2025
主題:	Cancer Molecular and Cellular Biology Therapeutic Research and Development DNA Damage and Repair Genomic instability Small Molecule Agents
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplementary Table S1 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment
著者:: Konjeti R. Sekhar (15400345)
出版事項: (2025)

Supplementary Table S1 from G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
著者:: Rongxin Zhang (15293341)
出版事項: (2025)

Supplementary Table S2 from G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
著者:: Rongxin Zhang (15293341)
出版事項: (2025)

Figure 1 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
著者:: Katrina M. Lappin (9340394)
出版事項: (2025)

Figure 2 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
著者:: Katrina M. Lappin (9340394)
出版事項: (2025)

Figure 3 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
著者:: Katrina M. Lappin (9340394)
出版事項: (2025)

Figure 4 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
著者:: Katrina M. Lappin (9340394)
出版事項: (2025)

Supplementary Table S2 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer
著者:: Félix Blanc-Durand (15049400)
出版事項: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
著者:: Min Wei (16918572)
出版事項: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
著者:: Min Wei (16918572)
出版事項: (2025)

Table 1_Mechanistic study of TFE3 breakage in TFE3-rearranged renal cell carcinoma: the perspective of non-canonical DNA structures and their stability.docx
著者:: Xiaopo Zhang (402895)
出版事項: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
著者:: Arun Kanakkanthara (14937731)
出版事項: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
著者:: Arun Kanakkanthara (14937731)
出版事項: (2025)

Deletion of the C-terminus of ATR leads to DNA damage and an increase of aberrant cells.
著者:: Gabriel L. A. da Silva (22676649)
出版事項: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
著者:: Sami Belhadj (15052341)
出版事項: (2025)

Supplementary Table S2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
著者:: Holly Tovey (16824233)
出版事項: (2025)

Supplementary Table S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
著者:: Holly Tovey (16824233)
出版事項: (2025)

Table S1 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
著者:: Aditi S. Khatpe (15293176)
出版事項: (2025)

Table S10 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
著者:: Aditi S. Khatpe (15293176)
出版事項: (2025)

Table S11 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
著者:: Aditi S. Khatpe (15293176)
出版事項: (2025)

Table S12 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
著者:: Aditi S. Khatpe (15293176)
出版事項: (2025)

Table S13 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
著者:: Aditi S. Khatpe (15293176)
出版事項: (2025)

Table S14 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
著者:: Aditi S. Khatpe (15293176)
出版事項: (2025)

Table S15 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
著者:: Aditi S. Khatpe (15293176)
出版事項: (2025)

Table S2 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
著者:: Aditi S. Khatpe (15293176)
出版事項: (2025)

Table S3 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
著者:: Aditi S. Khatpe (15293176)
出版事項: (2025)

Table S4 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
著者:: Aditi S. Khatpe (15293176)
出版事項: (2025)

Table S9 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
著者:: Aditi S. Khatpe (15293176)
出版事項: (2025)

Supplemental Table 1 from Polymorphisms in the Nonhomologous End-joining DNA Repair Pathway are Associated with HPV Integration in Cervical Dysplasia
著者:: Jennifer M. Geris (16426277)
出版事項: (2025)

Figure 1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
著者:: Gonzalo Rodriguez-Berriguete (15056057)
出版事項: (2025)

Figure 2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
著者:: Gonzalo Rodriguez-Berriguete (15056057)
出版事項: (2025)

Figure 3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
著者:: Gonzalo Rodriguez-Berriguete (15056057)
出版事項: (2025)

Figure 4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
著者:: Gonzalo Rodriguez-Berriguete (15056057)
出版事項: (2025)

Figure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
著者:: Gonzalo Rodriguez-Berriguete (15056057)
出版事項: (2025)

Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
著者:: Gonzalo Rodriguez-Berriguete (15056057)
出版事項: (2025)

Table S1 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
著者:: Lenka Stolarova (16547259)
出版事項: (2025)

Table S2 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
著者:: Lenka Stolarova (16547259)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_a1f5koq50i807hcedgphdt4qa7